Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, van Leeuwen R, Kunanusont C, Buranapraditkul S, Sirivichayakul S, Lange JM, Cooper DA, Phanuphak P. Kroon ED, et al. Among authors: ungsedhapand c. AIDS. 2000 Jul 7;14(10):1349-56. doi: 10.1097/00002030-200007070-00007. AIDS. 2000. PMID: 10930149 Clinical Trial.
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. Ruxrungtham K, et al. Among authors: ungsedhapand c. AIDS. 2000 Jul 7;14(10):1375-82. doi: 10.1097/00002030-200007070-00010. AIDS. 2000. PMID: 10930152 Clinical Trial.
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. Ungsedhapand C, et al. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):116-23. doi: 10.1097/00126334-200106010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11404532 Clinical Trial.
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team. Ungsedhapand C, et al. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701. doi: 10.1097/00126334-200406010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15167288 Clinical Trial.
Poor quality of life among untreated Thai and Cambodian children without severe HIV symptoms.
Bunupuradah T, Puthanakit T, Kosalaraksa P, Kerr SJ, Kariminia A, Hansudewechakul R, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Chuenyam T, Vonthanak S, Vun MC, Vibol U, Vannary B, Ruxrungtham K, Ananworanich J; PREDICT Study Group. Bunupuradah T, et al. AIDS Care. 2012;24(1):30-8. doi: 10.1080/09540121.2011.592815. Epub 2011 Jul 21. AIDS Care. 2012. PMID: 21777076 Free PMC article.
Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study.
Bunupuradah T, Kosalaraksa P, Vibol U, Hansudewechakul R, Sophonphan J, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Vonthanak S, Ananworanich J, Ruxrungtham K, Puthanakit T; Predict Study Group. Bunupuradah T, et al. AIDS Patient Care STDS. 2013 Nov;27(11):596-603. doi: 10.1089/apc.2013.0203. AIDS Patient Care STDS. 2013. PMID: 24191673 Free PMC article. Clinical Trial.
29 results